212 related articles for article (PubMed ID: 24962733)
1. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing.
Liao Z; Feng S; Ling P; Zhang G
J Thromb Thrombolysis; 2015 Feb; 39(2):228-34. PubMed ID: 24962733
[TBL] [Abstract][Full Text] [Related]
2. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials.
Tse G; Gong M; Li G; Wong SH; Wu WKK; Wong WT; Roever L; Lee APW; Lip GYH; Wong MCS; Liu T;
Br J Clin Pharmacol; 2018 Sep; 84(9):1868-1882. PubMed ID: 29704269
[TBL] [Abstract][Full Text] [Related]
3. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
5. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
Wang F; Guo J; Zhang A
J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
[TBL] [Abstract][Full Text] [Related]
7. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
Franchini M; Mengoli C; Cruciani M; Bonfanti C; Mannucci PM
J Thromb Haemost; 2014 Sep; 12(9):1480-7. PubMed ID: 25040440
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of genotype-guided dosing of warfarin.
Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
[TBL] [Abstract][Full Text] [Related]
9. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Kimmel SE; French B; Kasner SE; Johnson JA; Anderson JL; Gage BF; Rosenberg YD; Eby CS; Madigan RA; McBane RB; Abdel-Rahman SZ; Stevens SM; Yale S; Mohler ER; Fang MC; Shah V; Horenstein RB; Limdi NA; Muldowney JA; Gujral J; Delafontaine P; Desnick RJ; Ortel TL; Billett HH; Pendleton RC; Geller NL; Halperin JL; Goldhaber SZ; Caldwell MD; Califf RM; Ellenberg JH;
N Engl J Med; 2013 Dec; 369(24):2283-93. PubMed ID: 24251361
[TBL] [Abstract][Full Text] [Related]
10. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
11. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.
Dietz N; Ruff C; Giugliano RP; Mercuri MF; Antman EM
Int J Cardiol; 2020 Oct; 317():159-166. PubMed ID: 32505370
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
[TBL] [Abstract][Full Text] [Related]
14. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
[TBL] [Abstract][Full Text] [Related]
15. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
Cho SM; Lee KY; Choi JR; Lee KA
Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
17. Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.
Guo C; Kuang Y; Zhou H; Yuan H; Pei Q; Li J; Jiang W; Ng CM; Chen X; Huo Y; Cui Y; Wang X; Yu J; Sun X; Yu W; Chen P; Miao D; Liu W; Yu Z; Ouyang Z; Shi X; Lv C; Peng Z; Xiong G; Zeng G; Zeng J; Dai H; Peng J; Zhang Y; Xu F; Wu J; Chen X; Gong H; Yang Z; Wu X; Fang Q; Yang L; Li H; Tan H; Huang Z; Tang X; Yang Q; Tu S; Wang X; Xiang Y; Huang J; Wang X; Cai J; Jiang S; Huang L; Peng J; Gong L; Zou C; Yang G
Circ Genom Precis Med; 2020 Aug; 13(4):e002602. PubMed ID: 32510984
[TBL] [Abstract][Full Text] [Related]
18. Chinese Patients With Heart Valve Replacement Do Not Benefit From Warfarin Pharmacogenetic Testing on Anticoagulation Outcomes.
Hao Y; Yang J; Zheng X; Hu Y; Yan X; Zhang L
Ther Drug Monit; 2019 Dec; 41(6):748-754. PubMed ID: 31259883
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation.
Zhu Y; You J; Gu X; Zhu H; Liu J
Eur J Clin Pharmacol; 2023 Mar; 79(3):427-435. PubMed ID: 36708395
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.
Anand A; Hegde NC; Chhabra P; Purohit J; Kumar R; Gupta A; Lad DP; Mohindra R; Mehrotra S; Vijayvergiya R; Kumar B; Sharma V; Malhotra P; Ahluwalia J; Das R; Patil AN; Shafiq N; Malhotra S
Ann Hematol; 2024 Jun; 103(6):2133-2144. PubMed ID: 38634917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
